TScan Therapeutics Inc

For the period ended Dec 31, 2023. Filed Mar 6, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 6, 2024

TCRX$0.19+2.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Equity

(in thousands, except share data and issuance costs)

Additional · Total
Voting Common Stock · Non-voting Common Stock · Paid-In · Accumulated · Stockholders’
	Shares	Amount	Shares	Amount	Capital	Deficit	Equity
Balances at January 1, 2022	18,764,463	$2	5,143,134	$1	$252,933	$(92,158)	$160,778
Exercise of stock options	55,107	-	-	-	133	-	133
Vesting of restricted common stock	116,870	-	-	-	-	-	-
Issuance of common stock under ESPP plan	146,380	-	-	-	193	-	193
Stock-based compensation expense	-	-	-	-	4,551	-	4,551
Net loss	-	-	-	-	-	(66,221)	(66,221)
Balances at December 31, 2022	19,082,820	2	5,143,134	1	257,810	(158,379)	99,434
Exercise of stock options	316,441	-	-	-	711	-	711
Issuance of common stock, net of offering costs	23,287,134	2	-	-	42,412	-	42,414
Issuance of pre-funded warrants, net of offering costs	-	-	-	-	92,318	-	92,318
Conversion of non-voting common stock to voting common stock	866,546	-	(866,546)	-	-	-	-
Stock-based compensation expense	-	-	-	-	5,208	-	5,208
Net loss	-	-	-	-	-	(89,218)	(89,218)
Balances at December 31, 2023	43,552,941	$4	4,276,588	$1	$398,459	$(247,597)	$150,867

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.